Logo image of INMD

INMODE LTD (INMD) Stock Fundamental Analysis

NASDAQ:INMD - Nasdaq - IL0011595993 - Common Stock - Currency: USD

15.16  -0.05 (-0.33%)

After market: 15.1343 -0.03 (-0.17%)

Fundamental Rating

7

Overall INMD gets a fundamental rating of 7 out of 10. We evaluated INMD against 187 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making INMD a very profitable company, without any liquidiy or solvency issues. INMD may be a bit undervalued, certainly considering the very reasonable score on growth This makes INMD very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

INMD had positive earnings in the past year.
In the past year INMD had a positive cash flow from operations.
INMD had positive earnings in each of the past 5 years.
Each year in the past 5 years INMD had a positive operating cash flow.
INMD Yearly Net Income VS EBIT VS OCF VS FCFINMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

1.2 Ratios

Looking at the Return On Assets, with a value of 24.94%, INMD belongs to the top of the industry, outperforming 98.40% of the companies in the same industry.
With an excellent Return On Equity value of 28.38%, INMD belongs to the best of the industry, outperforming 97.33% of the companies in the same industry.
With an excellent Return On Invested Capital value of 15.86%, INMD belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for INMD is significantly above the industry average of 7.89%.
The 3 year average ROIC (22.89%) for INMD is well above the current ROIC(15.86%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 24.94%
ROE 28.38%
ROIC 15.86%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
INMD Yearly ROA, ROE, ROICINMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

With an excellent Profit Margin value of 44.80%, INMD belongs to the best of the industry, outperforming 98.40% of the companies in the same industry.
In the last couple of years the Profit Margin of INMD has grown nicely.
The Operating Margin of INMD (28.05%) is better than 96.79% of its industry peers.
INMD's Operating Margin has declined in the last couple of years.
INMD's Gross Margin of 80.03% is amongst the best of the industry. INMD outperforms 93.58% of its industry peers.
In the last couple of years the Gross Margin of INMD has declined.
Industry RankSector Rank
OM 28.05%
PM (TTM) 44.8%
GM 80.03%
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
INMD Yearly Profit, Operating, Gross MarginsINMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

INMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for INMD has been reduced compared to 1 year ago.
Compared to 5 years ago, INMD has more shares outstanding
There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INMD Yearly Shares OutstandingINMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
INMD Yearly Total Debt VS Total AssetsINMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

There is no outstanding debt for INMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.75
WACC9.07%
INMD Yearly LT Debt VS Equity VS FCFINMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

A Current Ratio of 8.73 indicates that INMD has no problem at all paying its short term obligations.
INMD has a better Current ratio (8.73) than 89.84% of its industry peers.
A Quick Ratio of 7.86 indicates that INMD has no problem at all paying its short term obligations.
INMD has a better Quick ratio (7.86) than 91.44% of its industry peers.
Industry RankSector Rank
Current Ratio 8.73
Quick Ratio 7.86
INMD Yearly Current Assets VS Current LiabilitesINMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for INMD have decreased strongly by -25.00% in the last year.
Measured over the past years, INMD shows a very strong growth in Earnings Per Share. The EPS has been growing by 22.97% on average per year.
Looking at the last year, INMD shows a very negative growth in Revenue. The Revenue has decreased by -15.84% in the last year.
Measured over the past years, INMD shows a very strong growth in Revenue. The Revenue has been growing by 20.35% on average per year.
EPS 1Y (TTM)-25%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-3.13%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-3%

3.2 Future

INMD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.28% yearly.
INMD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.35% yearly.
EPS Next Y-3.22%
EPS Next 2Y4.02%
EPS Next 3Y6.28%
EPS Next 5YN/A
Revenue Next Year-4.12%
Revenue Next 2Y0.26%
Revenue Next 3Y3.35%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
INMD Yearly Revenue VS EstimatesINMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
INMD Yearly EPS VS EstimatesINMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 8.56, the valuation of INMD can be described as very reasonable.
Based on the Price/Earnings ratio, INMD is valued cheaper than 97.33% of the companies in the same industry.
INMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.45.
INMD is valuated cheaply with a Price/Forward Earnings ratio of 7.87.
INMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. INMD is cheaper than 96.79% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.90. INMD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 8.56
Fwd PE 7.87
INMD Price Earnings VS Forward Price EarningsINMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INMD is valued cheaply inside the industry as 99.47% of the companies are valued more expensively.
INMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. INMD is cheaper than 97.86% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.86
EV/EBITDA 1.99
INMD Per share dataINMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The excellent profitability rating of INMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.37
EPS Next 2Y4.02%
EPS Next 3Y6.28%

More info and screens

0

5. Dividend

5.1 Amount

INMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INMODE LTD

NASDAQ:INMD (7/3/2025, 7:38:01 PM)

After market: 15.1343 -0.03 (-0.17%)

15.16

-0.05 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-28 2025-04-28/bmo
Earnings (Next)07-24 2025-07-24/bmo
Inst Owners72.46%
Inst Owner Change1.86%
Ins Owners10.65%
Ins Owner ChangeN/A
Market Cap958.26M
Analysts75.38
Price Target17.39 (14.71%)
Short Float %10.13%
Short Ratio3.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.98%
Min EPS beat(2)-20.27%
Max EPS beat(2)-13.69%
EPS beat(4)1
Avg EPS beat(4)-9.56%
Min EPS beat(4)-20.27%
Max EPS beat(4)8.88%
EPS beat(8)3
Avg EPS beat(8)-6.75%
EPS beat(12)7
Avg EPS beat(12)-0.58%
EPS beat(16)11
Avg EPS beat(16)2.13%
Revenue beat(2)0
Avg Revenue beat(2)-6.17%
Min Revenue beat(2)-9.96%
Max Revenue beat(2)-2.38%
Revenue beat(4)1
Avg Revenue beat(4)-7.11%
Min Revenue beat(4)-16.64%
Max Revenue beat(4)0.53%
Revenue beat(8)2
Avg Revenue beat(8)-6.51%
Revenue beat(12)6
Avg Revenue beat(12)-2.94%
Revenue beat(16)10
Avg Revenue beat(16)-0.79%
PT rev (1m)-8.05%
PT rev (3m)-20.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.53%
EPS NY rev (1m)-0.19%
EPS NY rev (3m)-13.35%
Revenue NQ rev (1m)0.23%
Revenue NQ rev (3m)-0.31%
Revenue NY rev (1m)-0.24%
Revenue NY rev (3m)-1.73%
Valuation
Industry RankSector Rank
PE 8.56
Fwd PE 7.87
P/S 2.44
P/FCF 7.86
P/OCF 7.82
P/B 1.55
P/tB 1.55
EV/EBITDA 1.99
EPS(TTM)1.77
EY11.68%
EPS(NY)1.93
Fwd EY12.7%
FCF(TTM)1.93
FCFY12.73%
OCF(TTM)1.94
OCFY12.79%
SpS6.21
BVpS9.8
TBVpS9.8
PEG (NY)N/A
PEG (5Y)0.37
Profitability
Industry RankSector Rank
ROA 24.94%
ROE 28.38%
ROCE 17.41%
ROIC 15.86%
ROICexc 84.14%
ROICexgc 84.14%
OM 28.05%
PM (TTM) 44.8%
GM 80.03%
FCFM 31.08%
ROA(3y)23.69%
ROA(5y)26.18%
ROE(3y)26.67%
ROE(5y)29.84%
ROIC(3y)22.89%
ROIC(5y)25.97%
ROICexc(3y)532.49%
ROICexc(5y)5023.19%
ROICexgc(3y)532.49%
ROICexgc(5y)5023.19%
ROCE(3y)25.13%
ROCE(5y)28.51%
ROICexcg growth 3Y-60.68%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.68%
ROICexc growth 5YN/A
OM growth 3Y-15.26%
OM growth 5Y-5.64%
PM growth 3Y-0.16%
PM growth 5Y3.28%
GM growth 3Y-1.88%
GM growth 5Y-1.59%
F-Score6
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 87.11%
Cap/Sales 0.16%
Interest Coverage 250
Cash Conversion 110.65%
Profit Quality 69.38%
Current Ratio 8.73
Quick Ratio 7.86
Altman-Z N/A
F-Score6
WACC9.07%
ROIC/WACC1.75
Cap/Depr(3y)144.54%
Cap/Depr(5y)147.73%
Cap/Sales(3y)0.22%
Cap/Sales(5y)0.23%
Profit Quality(3y)91.09%
Profit Quality(5y)96.73%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-4.52%
EPS 5Y22.97%
EPS Q2Q%-3.13%
EPS Next Y-3.22%
EPS Next 2Y4.02%
EPS Next 3Y6.28%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y3.36%
Revenue growth 5Y20.35%
Sales Q2Q%-3%
Revenue Next Year-4.12%
Revenue Next 2Y0.26%
Revenue Next 3Y3.35%
Revenue Next 5YN/A
EBIT growth 1Y-36.29%
EBIT growth 3Y-12.42%
EBIT growth 5Y13.55%
EBIT Next Year-31.82%
EBIT Next 3Y-5%
EBIT Next 5YN/A
FCF growth 1Y-27.92%
FCF growth 3Y-8.8%
FCF growth 5Y16.5%
OCF growth 1Y-28.22%
OCF growth 3Y-8.8%
OCF growth 5Y16.36%